anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our primary outcome measurement is body mass index (BMI) as this is now recommended by major health organizations as the preferred measure for the determination of obesity. All children at YMCA After School Programs will receive either YMCA-PAN or YMCA standard care; however, we will only follow children in grades kindergarten through second grade (K-2). For children in grades K-2, we will determine if 3 years of increased physical activity and snacks lower in energy and fat and higher in nutrient density will diminish gains in BMI. We have specifically targeted an increase of moderate to vigorous physical activity (MVPA) by 225 minutes per week that is delivered in YMCA-PAN as this is a compromise between the recommendations suggested by Healthy People 2010 and the Institute of Medicine (IOM) and is administratively feasible within the existing YMCA After School Programs. YMCA-PAN would exceed the Healthy People 2010 guidelines and would provide the majority of PA for the IOM guidelines. Children would satisfy the IOM guidelines with just 15 additional minutes of MVPA accrued throughout the day in physical education class or free play. Finally, YMCA PAN would provide opportunity for PA at the very time the guidelines call "most critical:" the hours between 3 and 6pm when children have finished the school day and frequently are sedentary. For the nutritional component, we are targeting snacks, as snacks are part of the YMCA after school programs, snacks contribute significantly to 24 hour energy intake, children are increasingly in control of the snacks they consume, and we have previously diminished 24 hour energy intake and fat intake using snacks in elementary school children.

We will provide this intervention using regular YMCA staff and use the regular time periods for PA that exist in the YMCA after school programs. We will also use the regular YMCA staff to provide snacks. Specifically, we expect that children receiving YMCA-PAN will show smaller changes in BMI after 3 years of the intervention when compared to children not receiving YMCA-PAN (i.e. standard, existing YMCA after school program or "YMCA standard care").
FIELD: organic chemistry. SUBSTANCE: product - macrolide compounds of the formula (I) given in the invention description. Reagent 1: compound of the formula (II) given in description. Reagent 2: NH 2 OR 3  where R 3  - as indicated in description. Reaction conditions: temperature is 10-80 C for 1-24 h in the medium of inert solvent following by isolation of the end product of the formula (I). Synthesized compounds are used in agriculture and cause lethality of ticks at the range 92-100%. EFFECT: improved method of synthesis, increased effectiveness of the end products. 1 tbl
Technology is described for searching for treatment related output defined by bioinformatic markers of a person. The method can include receiving a biologic risk profile for the person which defines a plurality of disease risks expressed in bioinformatic markers. A disease interest profile representing diseases in which the person has interests may also be received. Disease keywords may be retrieved from the biologic risk profile and the disease interest profile. The disease keywords may be weighted using the disease interest profile. Further, the disease keywords may be mapped to medical publications, medical trials, or medical treatments to form a medical mapping. Disease keywords with a weighting above a defined weight threshold may be selected and disease keywords below the defined weight threshold may be filtered out. An asset that is associated with the disease keywords may be identified using a machine learning model to process the disease keywords and weightings.
Diabetes mellitus (DM) is a chronic metabolic disorder characterized by an elevated level of blood glucose due to the absence of insulin secretion, ineffectiveness, or lack of uptake of secreted insulin in the body. The improperly diagnosed and poorly managed DM can cause severe damage to organs in the body like the nerves, eyes, heart, and kidneys. This study was aimed at investigating the effect of Clostridium butyricum (probiotic) with magnesium supplementation to evaluate the effect on gut microbial dysbiosis and blood glucose levels. In the laboratory, 6-8 weeks old 24 male albino rats weighing 200-250 g were given free access to water and food. Diabetes was induced using streptozotocin (60 mg/kg) in overnight fasted rats. Diabetic rats were randomly divided into four groups (n = 6, 6 replicates in each group). Metformin (100 mg/kg/day) with a standard basal diet was provided to control group (G0), Clostridium butyricum (1.5 × 105 CFU/day) with standard basal diet was provided to treatment group (G1), magnesium (500 mg/kg/day) was provided to group (G2). Clostridium butyricum (1.5 × 105 CFU/day) and magnesium (300 mg/kg/day) in combination with a standard basal diet was provided to group (G3). Blood Glucose, Magnesium blood test and microbial assay were done. Random blood glucose levels were monitored twice a week for 21 days and were represented as mean of each week. The results conclude that Clostridium butyricum (1.5 × 105 CFU) is very effective in balancing random blood glucose levels from 206.6 ± 67.7 to 85.1 ± 3.8 (p = 0.006) compared to other groups (p > 0.005). The results of stool analysis showed that Clostridium butyricum as probiotic restores microbial dysbiosis as evident by the 105 CFU Clostridium butyricum load in G1, which was higher than G0, G2 and G3 which were 103 and 104 CFU respectively. The findings of this study conclude that Clostridium butyricum supplementation improved blood glucose levels and intestinal bacterial load in type II diabetes mellitus.
the specific effect of IMT on expiratory muscle strength and abdominal wall thickness during weaning remains unclear. To address this significant research gap, the primary objective of our study was to evaluate the effect of IMT after extubation on expiratory muscle strength and abdominal muscle thickness in respiratory ICU patients. On the other hand the investigators established reference values for ultrasonographic measurements in healthy control subjects as a comparative arm. To the best of our knowledge, this is the first study to examine the ultrasonographic effects of IMT on the expiratory muscle thickness after extubation. The investigators believe that our study may contribute to related literature in this context and guide future research as a pioneer with its unique value. In this single-blind randomized controlled study, 20 patients were divided into two groups: IMT and conventional physiotherapy(CP). In order to establish normative data for abdominal muscle thickness, ten healthy controls were included in the study. The CP group received CP and the IMT group received CP+IMT for five days following extubation. The thicknesses of the external oblique abdominal(EOA),internal oblique sbdominal(IOA), transversus abdominus (TRA) and rectus abdominis (RA) muscleswere evaluated The maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) were recorded.
Semi-structured focus groups of 6 to 8 women per group will be conducted. Women in these groups will be of higher socioeconomic status (SES) and will be African-American/Black.
Fatigue is commonly associated with myasthenia gravis (MG), but factors contributing to fatigue development in MG are incompletely understood. This nationwide cross-sectional registry study included 1464 patients diagnosed with autoimmune MG, recruited between February 2019 and April 2023. Frequency and severity of fatigue was assessed at study inclusion using the patient-reported Chalder Fatigue Questionnaire (CFQ). Frequency of fatigue was 59%. Fatigue severity strongly correlated with both patient-reported and physician-assessed MG outcome measures (MG-ADL, MG-QoL15, QMG and MGFA classes) and was associated with a history of myasthenic exacerbation and/or myasthenic crises and a delay in diagnosis of more than 1 year after symptom onset. Fatigue was more prevalent in women and coincided with symptoms of depression, anxiety, and sleep dissatisfaction. Differences in fatigue severity were observed between antibody (ab) subgroups, with highest fatigue severity in LRP4-ab-positive patients and lowest fatigue severity in AChR-ab-positive patients. Fatigue is a frequent and clinically highly relevant symptom of MG. Early diagnosis and prevention of MG crises may limit the long-term burden of fatigue in patients with MG.
PROBLEM TO BE SOLVED: To obtain the subject new compound having a nitric oxide synthase(NOS) inhibiting action and usable as a therapeutic agent for cerebrovascular diseases, head injury, Parkinson's disease, Alzheimer's disease, etc. SOLUTION: This compound is represented by formula I [R1 is a tricyclic heterocyclic group, whose arbitrary position may be substituted with a lower alkyl and/or a halogen, having one or more nitrogen group; R2 is phenyl, pyridyl or a group of formula II (R3 is a halogen, etc.)] or its tautomer, e.g. 7-(S- ethylisothioureido)-1,2,3,3a,4,5-hexahydropyrrolo[1,2-a]quinazoline. The compound of formula I can be obtained by a different synthetic method according to the kind of R2 by using a readily available compound of formula II as a starting raw material. Thereby, objective compound having inhibiting action n calcium- dependent NOS and apparently nondependent NOS is provided.
We aim to conduct a pilot randomized controlled trial comparing 2 symptom management programs for older adults with self-reported memory problems and chronic pain: Active Brains 1 Active Brains 2. We will assess how each program may help in improving coping with pain and coping with cognitive functioning. We will explore feasibility, acceptability, and credibility and within group changes in physical, emotional and cognitive functioning.

Each group meets for 8 90 minute sessions over a secure video platform. Each group has 5-8 participants. Participants receive a treatment manual. There are 2 assessment points: baseline, and post program. Assessments involve questionnaires, a walk test, and objective step count with ActiGraphs for 1 week.
Any patient with a 25-OH vitamin D level(s) always lower than 40 ng/ml (low level) with subsequent level(s) in the 40 ng/ml to 100 ng/ml range. The 40 ng/ml to 100 ng/ml range is maintained for three years.
The present invention provides substantially purified cryptdin peptides having a consensus amino acid sequence as follows: X1-C-X2-C-R-X3-C-X4-E-X5-G-X6-C-X7-C-C-X8 wherein X1 is 3-6 amino acids; X2 is one amino acid; X3 is 2 or 3 amino acids; X4 is three amino acids; X5 is three amino acids; X6 is one amino acid; X7 is 6 to 10 amino acids; and X8 is 0 to 7 amino acids. The invention further provides substantially purified cryptdin peptides having a consensus amino acid sequence as follows: X1-L-X2-C-Y-C-R-X3-C-K-X4-E-R-X5-G-T-C-X6-C-C-X7 wherein X1 is one to four amino acids; X2 is one amino acid; X3 is three amino acids; X4 is two amino acids; X5 is two amino acids; and X6 is six to nine amino acids; and X7 is zero to seven amino acids. The illustrated embodiments have amino acids selected from the group consisting of the following sequences: LRDLVCYCRSRGCKGRERMNGTCRKGHLLYTLCCR LRDLVCYCRTRGCKRRERMNGTCRKGHLMYTLCCR LRDLVCYCRKRGCKRRERMNGTCRKGHLMYTLCCR GLLCYCRKGHCKRGERVRGTCGIRFLYCCPR LSKKLICYCRIRGCKRRERVFGTCRNLFLTFVFCC LKQCHCRKFCRPYEKAEGSCRPGLFIKRKICCIQQWTPG In another embodiment, the inventions provide analogs devoid of amino acids to the N-terminal of the first cysteine. Cryptdins are typically characterized by being naturally found in the epithelial cells of the small intestine being cationic, being between 30 and 40 amino acids in length, having 3 to 6 amino acids to the N-terminal of the first cysteine residue, exhibiting specific antimicrobial activity against intestinal pathogens and being relatively non-toxic to cells of the host organism. However, there may be diversity in these structural and functional characteristics. The present invention provides a method for detecting inflammatory pathologies in the subject and, further, provides a method for treating an infectious process of the intestine or other organ of the patient by administering cryptdin in a physiologically acceptable medium.
Multiple rare structural variants of relatively recent evolutionary origin are recognized as important risk factors for schizophrenia (SZ) and other neurodevelopmental disorders (e.g., autism spectrum disorders, mental retardation, epilepsy) with odds ratios as high as 7-30 (Sebat et al. 2009; Malhotra et al. 2011; Heinzen et al. 2010; Weiss et al. 2008; McCarthy et al. 2009). We have found a de novo structural rearrangement on chromosome 9p24.1 in two psychotic patients. One of the genes in this region is the gene encoding glycine decarboxylase (GLDC), which affects brain glycine metabolism. GLDC encodes the glycine decarboxylase or glycine cleavage system P-protein, which is involved in degradation of glycine in glia cells. Carriers of the GLDC triplication would be expected to have low levels of brain Gly, resulting in NMDA receptor-mediated hypofunction, which has been strongly implicated in the pathophysiology of schizophrenia (Olney \& Farber, 1995; Coyle, 2006; Javitt, 2007).

There is an extensive literature on the effects of NMDA enhancing agents on positive, negative, and depressive symptoms and on neurocognitive function (see Tsai \& Lin, 2010; Lin et al. 2011 for reviews). Although many studies have reported positive results in at least one symptom domain (Heresco-Levy et al. 1996, 1999, 2004; Tsai et al. 1998, 1999, 2004, 2006; Javitt et al. 2001; Goff et al. 1996; Lane et al. 2008), the results of other studies have been negative or ambiguous (Goff et al. 1999; Evins et al. 2000; Duncan et al. 2004; van Berckel et al. 1999). Factors likely to contribute to this variability include: mechanism of action of the agent, compliance, concurrent treatment with first- vs second generation antipsychotic drugs, baseline glycine blood levels, presence/absence of kynurenine pathway metabolic abnormalities (Wonodi et al. 2010; Erhardt et al. 2007) and individual differences in brain glycine uptake and metabolism (Kaufman et al. 2009; Buchanan et al. 2007). Genetic variants that impact the synthesis and breakdown of glycine, glutamate, or other modulators of NMDA receptor function are also likely to have significant effects. Although glycine augmentation has shown variable efficacy in patients unselected for having a mutation that would be expected to lower brain glycine levels, the GLDC triplication in the two carriers in this study would be expected to result in unusually low brain glycine levels, supporting its therapeutic potential as an augmentation strategy.

Thus, it is important to evaluate the therapeutic efficacy of glycine augmentation in individuals in whom there is a high prior probability of therapeutic benefit and to characterize the neurobiology of this mutation in terms of brain metabolites, brain function, and the pharmacokinetics of glycine metabolism using well-established methods (Kaufman et al. 2009; Prescot et al. 2006; Martinez et al. 2008; Butler et al. 2001; Jensen et al. 2009; Ongur et al. 2008).
Intracerebral hemorrhage (ICH) is a stroke subtype with a high mortality rate (~ 40%). After ICH, the mass effect of the hematoma and edema contribute to raised intracranial pressure (ICP) and poor outcome. Endogenous compensatory mechanisms that blunt ICP elevations include redirection of venous blood and cerebrospinal fluid, along with brain tissue compliance (e.g., decreased cell volume, increased cell density); however, these limited reserves can be exhausted after severe stroke, resulting in decompensated ICP that requires careful clinical management. Management strategies can include administration of hypertonic saline (HTS), an osmotic agent that putatively attenuates edema, and thereby ICP elevations. Evidence regarding the efficacy of HTS treatment following ICH remains limited. In this study, adult male rats were given a collagenase-induced striatal ICH and a bolus of either 3% HTS or 0.9% saline vehicle at 2- and 14-hours post-stroke onset. Neurological deficits, edema, ipsilateral cell volume and density (in areas S1 and CA1), and contralateral CA1 ultrastructural morphology were assessed 24 h post-ICH. Animals had large bleeds (median 108.2 µL), extensive edema (median 83.9% brain water content in ipsilateral striatum), and evident behavioural deficits (median 5.4 neurological deficit scale score). However, HTS did not affect edema (p ≥ 0.4797), behaviour (p = 0.6479), cell volume (p ≥ 0.1079), or cell density (p ≥ 0.0983). Qualitative ultrastructural assessment of contralateral area CA1 suggested that HTS administration was associated with paradoxical cellular swelling in ICH animals. Overall, there was no benefit with administering 3% HTS after ICH.
A substance for the treatment of liver damage having anti-hepatoxic, anti-inflammatory and anti-lipaemic activity is prepd from a broth made from mammalian liver inoculated with Pseudomonas strain pref. P. syringae or P. fluoreszenz. The subst. when undergoing electrophoresis in alkaline buffer migrates to the negative pole. It is eluted from an ion exchange column formed from cross-linked dextrans having diethylaminoaceto functional gps. in fractions between polarities 0.35 and 0.60 and 275-350 ml solvent.
Subjects assigned to this arm will undergo the same geriatric, neuropsychologic and audiologic evaluations administered to patients of the "Standard-of-Care" and "Treatment" arms at the same time points (baseline, 3 months and 1 year). These subjects will not undergo any surgical procedure and will therefore not be evaluated for post-operative complications or delirium occurrence.
The multifactorial intervention will be determined by the risk profile and risk markers of each individual and the participants will be allocated to Semaglutide, sotagliflozin or finerenone. The intervention will also comprise more ambitious treatment targets for blood pressure and lipid levels. In addition, all participants will take aspirin 75 mg OD.
Ten percent of adults aged ≥ 65 years and fifty percent of adults ≥ 85 years exhibit cognitive impairment. Dementia treatment cost $277 billion in 2018 and is predicted to surpass $500 billion with the aged population reaching 70 million by 2030 in America. In addition, 50% of older adults experience poor sleep quality, including fragmented nighttime sleep, reduced sleep efficiency, and earlier bedtime and wake-up times. Consequently, millions of Americans are at risk for both cognitive impairment, including Alzheimer's Disease and other dementias, and disrupted sleep. Sleep disruptions alter underlying circadian rhythms and synaptic plasticity in the hippocampus, as well as reduce expression of brain-derived neurotrophic factor (BDNF) - elements associated with impaired memory, dementia, and Alzheimer's Disease. Importantly, sleep disturbances and mild cognitive impairment may appear several years before the development of clinical dementia. Therefore, interventions that improve sleep may prevent cognitive impairment and would have substantial clinical importance. Pre-clinical animal models suggest that enhancing the availability of nicotinamide adenine dinucleotide (NAD+) may reduce cognitive decline and support sleep quality by boosting mitochondrial function and BDNF expression. Additionally, supplementation with NAD+ precursor nicotinamide riboside (NR), a form of vitamin B3, improves cognition in aged mice. The hypothesis for this study is that NR supplementation will enhance cognition by improving objective sleep duration and sleep quality in older persons. To test the hypothesis, this study will measure the benefits of NR supplementation on sleep and cognition in older Veterans and determine the role of BNDF as a potential biomarker of sleep quality.
Non-small-cell lung cancer (NSCLC) is a heterogeneous disease that may have several genetic alterations in oncogenes responsible for progression. 30-40% of NSCLC patients carry mutations affecting the Ras/MAPK pathway, while alterations in receptor tyrosine kinases (RTKs) are found in approximately 25-35% of cases. More than half of the latter are in the Epithelial Growth Factor Receptor (EGFR) gene and have been extensively studied. In the remaining cases, several genes are involved, each with lower frequencies, ranging from around 1% to 5%, depending on the studies. Despite the wide availability of inhibitors, progression remains inevitable due to the emergence of drug resistance mechanisms. The mechanisms by which resistance can be established are essentially of three types: amplification of the target gene, activation of other signal translation pathways (by-pass track) and the occurrence of mutations in the tyrosine kinase domain of the target protein. Liquid biopsy with circulating tumour DNA (ctDNA) analysis provides a non-invasive surrogate method to identify somatic mutations by means of a simple blood sample, without risk to the patient. Moreover, liquid biopsy, by collecting ctDNA from different metastatic sites, could better reflect tumour heterogeneity, both spatial and temporal, and could, therefore, constitute a simple method of longitudinal monitoring during treatment, possibly making it possible to identify relapse early before clinical manifestation. This single-centre prospective study is aimed at analysing, by means of liquid biopsy with next generation sequencing analysis on ctDNA, resistance mutations arising during therapy with selective inhibitors in patients with RTK-positive NSCLC or with mutations in the Ras/MAPK pathway, treated at the San Gerardo Hospital, Monza.
The current invention discloses a distinct and unique group of Crustacean antimicrobial peptides (AMP) called 'Hyasins'. These novel AMPs are isolated from Crustaceans, more particularly from decapods, and comprise the RPRPF motif in combination with the so-called 'PR-39 motif' RxxPxxP. In a preferred embodiment the peptides are derived from the crab Hyas araneus. Most interestingly, the present peptides are the first Crustacean AMPs with therapeutic potential beyond infective disease. The invention also relates to DNA or RNA encoding said peptides, vectors and cell lines, kits, as well as methods of preparation, methods of treatment and use of the Hyasins. In addition to antibacterial effects, Hyasins may be effective against viral infections, inflammation, ulcers and wounds, as well as cancer and metastatic transformation, inhibition of proteasome activity, development and differentiation of cells.
The invention discloses a pharmaceutical composition treating chronic constipation and a preparation method thereof. The pharmaceutical composition comprises western medicine ingredients, traditional Chinese medicine ingredients, a functional dietary supplementing agent, cereal powder and cereal syrup; the western medicine ingredients are alpha-pyrrolidone, aliphatic acid monoglyceride, dehydroabietylamine, PEG-4000 and erucic acid; the traditional Chinese medicine ingredients comprise effective ingredients of annual cassia, gymnoganyrus flablliformis Harv., polyopes polyideoides Okam. and cassia nomame (Sieb.) Kitag.; and the functional dietary supplementing agent is prepared from  populus tomentosa Carr seed powder and apple powder. The pharmaceutical composition can fully give play to curative effect of western medicine and traditional Chinese medicine, treats severe chronic constipation, and is capable of substantially improving intestinal functions for a short period, and mitigating constipation symptoms without side effect. The pharmaceutical composition provides balance protein, fat, carbohydrates, vitamins, mineral matters, cellulose and other nutrients for patients, also contains dietary fiber ingredient, helps to increase intestinal motility, improve intestinal function and fundamentally restore intestinal injury, and does not easily cause recurrence after a patient is healed.